Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial

IMPORTANCE: Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising resu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: He, MinKe, Li, QiJiong, Zou, RuHai, Shen, JingXian, Fang, WanQiang, Tan, GuoSheng, Zhou, YuanMin, Wu, XiaoPing, Xu, Li, Wei, Wei, Le, Yong, Zhou, ZhongGuo, Zhao, Ming, Guo, Ying, Guo, RongPing, Chen, MinShan, Shi, Ming
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2019
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512278/
https://ncbi.nlm.nih.gov/pubmed/31070690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0250
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky